Literature DB >> 3385359

Recombinant human tumor necrosis factor induces acute reductions in food intake and body weight in mice.

S H Socher1, A Friedman, D Martinez.   

Abstract

We examined the effects of treatment with rHuTNF on food consumption and body weight in C3H/HeJ mice. rHuTNF was administered intraperitoneally either by injections of 3, 12, or 24 micrograms twice a day or by implantation of osmotic pumps that released 0.75, 3, or 12 micrograms per day. Dose-dependent reductions in both food intake and weight were induced by rHuTNF. However, in spite of continued exposure to rHuTNF, the mice developed a resistance to rHuTNF and resumed their pretreatment food intake and weight. Non-immunological factors may play a role in the development of this tolerance, since it developed rapidly and faded within 2 wk of cessation of exposure to rHuTNF.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3385359      PMCID: PMC2189683          DOI: 10.1084/jem.167.6.1957

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  16 in total

Review 1.  Metabolic approaches to cancer cachexia.

Authors:  D H Lawson; A Richmond; D W Nixon; D Rudman
Journal:  Annu Rev Nutr       Date:  1982       Impact factor: 11.848

2.  Uncomplicated starvation versus cancer cachexia.

Authors:  M F Brennan
Journal:  Cancer Res       Date:  1977-07       Impact factor: 12.701

3.  Growing tumors induce hypersensitivity to endotoxin and tumor necrosis factor.

Authors:  J Bartholeyns; M Freudenberg; C Galanos
Journal:  Infect Immun       Date:  1987-09       Impact factor: 3.441

4.  Cachexia of malignancy: potential role of insulin in nutritional management.

Authors:  P S Schein; D Kisner; D Haller; M Blecher; M Hamosh
Journal:  Cancer       Date:  1979-05       Impact factor: 6.860

Review 5.  Cancer cachexia in man: a review.

Authors:  A J Strain
Journal:  Invest Cell Pathol       Date:  1979 Jul-Sep

6.  Tumors secreting human TNF/cachectin induce cachexia in mice.

Authors:  A Oliff; D Defeo-Jones; M Boyer; D Martinez; D Kiefer; G Vuocolo; A Wolfe; S H Socher
Journal:  Cell       Date:  1987-08-14       Impact factor: 41.582

7.  Binding of human tumor necrosis factor to high affinity receptors on HeLa and lymphoblastoid cells sensitive to growth inhibition.

Authors:  C Baglioni; S McCandless; J Tavernier; W Fiers
Journal:  J Biol Chem       Date:  1985-11-05       Impact factor: 5.157

Review 8.  Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor).

Authors:  A Cerami; Y Ikeda; N Le Trang; P J Hotez; B Beutler
Journal:  Immunol Lett       Date:  1985       Impact factor: 3.685

9.  Peculiarities of hyperlipidaemia in tumour patients.

Authors:  V M Dilman; L M Berstein; M N Ostroumova; Y V Tsyrlina; A G Golubev
Journal:  Br J Cancer       Date:  1981-05       Impact factor: 7.640

10.  Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells.

Authors:  B Beutler; J Mahoney; N Le Trang; P Pekala; A Cerami
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

View more
  17 in total

1.  Activation of macrophages in an experimental rat model of arthritis induced by Erysipelothrix rhusiopathiae infection.

Authors:  H Renz; U Gentz; A Schmidt; T Dapper; M Nain; D Gemsa
Journal:  Infect Immun       Date:  1989-10       Impact factor: 3.441

2.  Effects of continuously administered murine interleukin-1 alpha: tolerance development and granuloma formation.

Authors:  I G Otterness; H W Golden; W H Brissette; P A Seymour; G O Daumy
Journal:  Infect Immun       Date:  1989-09       Impact factor: 3.441

3.  Treatment with recombinant human tumor necrosis factor-alpha protects rats against the lethality, hypotension, and hypothermia of gram-negative sepsis.

Authors:  H R Alexander; B C Sheppard; J C Jensen; H N Langstein; C M Buresh; D Venzon; E C Walker; D L Fraker; M C Stovroff; J A Norton
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

4.  Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters.

Authors:  C Grunfeld; C Zhao; J Fuller; A Pollack; A Moser; J Friedman; K R Feingold
Journal:  J Clin Invest       Date:  1996-05-01       Impact factor: 14.808

5.  Tumour necrosis factor production and cell-mediated immunity in anorexia nervosa.

Authors:  A Schattner; M Steinbock; R Tepper; A Schonfeld; N Vaisman; T Hahn
Journal:  Clin Exp Immunol       Date:  1990-01       Impact factor: 4.330

6.  Tumor necrosis factor-alpha contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes.

Authors:  T G Kirchgessner; K T Uysal; S M Wiesbrock; M W Marino; G S Hotamisligil
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

7.  Metabolic effects of cachectin/tumor necrosis factor are modified by site of production. Cachectin/tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominantly acute anorexia.

Authors:  K J Tracey; S Morgello; B Koplin; T J Fahey; J Fox; A Aledo; K R Manogue; A Cerami
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

8.  Gastric leptin and Helicobacter pylori infection.

Authors:  T Azuma; H Suto; Y Ito; M Ohtani; M Dojo; M Kuriyama; T Kato
Journal:  Gut       Date:  2001-09       Impact factor: 23.059

9.  Regional induction of tumor necrosis factor alpha expression in the mouse brain after systemic lipopolysaccharide administration.

Authors:  C D Breder; C Hazuka; T Ghayur; C Klug; M Huginin; K Yasuda; M Teng; C B Saper
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

10.  Immunodeficiency associated with anorexia nervosa is secondary and improves after refeeding.

Authors:  L M Allende; A Corell; J Manzanares; D Madruga; A Marcos; A Madroño; A López-Goyanes; M A García-Pérez; J M Moreno; M Rodrigo; F Sanz; A Arnaiz-Villena
Journal:  Immunology       Date:  1998-08       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.